MAPK8 and breast cancer: The results showed that juglanin (5 and 10 mg/kg, i.p., for 7 days) inhibited the growth of human breast cancer xenografts, with an increase in the levels of activated caspases, LC3 I and II, and JNK phosphorylation [87].